By AdjAssocProf Craig Haifer

Journal articles

Chetwood JD; Paramsothy S; Haifer C; Leong RW; Kaakoush NO, 2023, 'Key metabolomic alterations are associated with ulcerative colitis disease state and activity: A validation analysis', Gut, http://dx.doi.org/10.1136/gutjnl-2023-330196

Haifer C; Luu LDW; Paramsothy S; Borody TJ; Leong RW; Kaakoush NO, 2023, 'Microbial determinants of effective donors in faecal microbiota transplantation for UC', Gut, 72, pp. 90 - 100, http://dx.doi.org/10.1136/gutjnl-2022-327742

Haifer C; Paramsothy S; Kaakoush NO; Leong RW, 2022, 'Oral faecal microbiota transplantation in ulcerative colitis – Authors' reply', The Lancet Gastroenterology and Hepatology, 7, pp. 286 - 287, http://dx.doi.org/10.1016/S2468-1253(22)00045-0

Haifer C; Paramsothy S; Kaakoush NO; Saikal A; Ghaly S; Yang T; Luu LDW; Borody TJ; Leong RW, 2022, 'Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial', The Lancet Gastroenterology and Hepatology, 7, pp. 141 - 151, http://dx.doi.org/10.1016/S2468-1253(21)00400-3

Haifer C; Saikal A; Paramsothy R; Kaakoush NO; Leong RW; Borody TJ; Kamm MA; Paramsothy S, 2021, 'Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy', Gut, 70, pp. 2210 - 2211, http://dx.doi.org/10.1136/gutjnl-2020-323581

Haifer C; Saikal A; Paramsothy R; Kaakoush NO; Leong RW; Borody TJ; Kamm MA; Paramsothy S, 2021, 'Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy', GUT, 70, pp. 2210 - 2210, http://dx.doi.org/10.1136/gutjnl-2020-323581

Srinivasan A; Haifer C; Thin L, 2021, 'Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab', Medical Journal of Australia, 215, pp. 435, http://dx.doi.org/10.5694/mja2.51303

Srinivasan A; Haifer C; Thin L, 2021, 'Editorial: outcomes following a second switch—evaluating clinical outcomes and patient perspectives in IBD', Alimentary Pharmacology and Therapeutics, 53, pp. 1038 - 1039, http://dx.doi.org/10.1111/apt.16325

Haifer C; Paramsothy S; Borody TJ; Clancy A; Leong RW; Kaakoush NO, 2021, 'Long-term bacterial and fungal dynamics following oral lyophilized fecal microbiota transplantation in clostridioides difficile infection', mSystems, 6, http://dx.doi.org/10.1128/MSYSTEMS.00905-20

Haifer C; Srinivasan A; An YK; Picardo S; van Langenberg D; Menon S; Begun J; Ghaly S; Thin L, 2021, 'Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study', Medical Journal of Australia, 214, pp. 128 - 133, http://dx.doi.org/10.5694/mja2.50824

Haifer C; Leong RW; Paramsothy S, 2020, 'The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease', Current Opinion in Pharmacology, 55, pp. 8 - 16, http://dx.doi.org/10.1016/j.coph.2020.08.009

Haifer C; Kelly CR; Paramsothy S; Andresen D; Papanicolas LE; McKew GL; Borody TJ; Kamm M; Costello SP; Andrews JM; Begun J; Chan HT; Connor S; Ghaly S; Johnson PDR; Lemberg DA; Paramsothy R; Redmond A; Sheorey H; Van Der Poorten D; Leong RW, 2020, 'Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice', Gut, 69, pp. 801 - 810, http://dx.doi.org/10.1136/gutjnl-2019-320260

Haifer C; Lawrance IC; Center JR; Clarke MW; Hart PH; Eisman JA; Lucas R; Ghaly S, 2019, 'Vitamin D metabolites are lower with active Crohn’s disease and spontaneously recover with development of remission', Therapeutic Advances in Gastroenterology, 12, http://dx.doi.org/10.1177/1756284819865144

Pudipeddi A; Kariyawasam V; Haifer C; Baraty B; Paramsothy S; Leong RWL, 2019, 'Safety of drugs used for the treatment of Crohn’s disease', Expert Opinion on Drug Safety, 18, pp. 357 - 367, http://dx.doi.org/10.1080/14740338.2019.1612874

Chan W; Shim HH; Ng SC; Liu J; Inglis C; Greveson K; Baraty B; Haifer C; Leong RWL, 2018, 'A global survey of gastroenterologists' travel advice to patients with inflammatory bowel disease on immunosuppressive agents and management of those visiting tuberculosis-endemic areas', Journal of Crohn's and Colitis, 12, pp. 1261 - 1269, http://dx.doi.org/10.1093/ecco-jcc/jjy110

Sood S; Haifer C; Yu L; Pavlovic J; Gow PJ; Jones RM; Visvanathan K; Angus PW; Testro AG, 2018, 'Early viral-specific T-cell testing predicts late cytomegalovirus reactivation following liver transplantation', Transplant Infectious Disease, 20, http://dx.doi.org/10.1111/tid.12934

Chan W; Lynch N; Bampton P; Chang J; Chung A; Florin T; Hetzel DJ; Jakobovits S; Moore G; Pavli P; Radford-Smith G; Thin L; Baraty B; Haifer C; Yau Y; Leong RWL, 2018, 'Entyvio lengthen dose-interval study: Lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease', European Journal of Gastroenterology and Hepatology, 30, pp. 735 - 740, http://dx.doi.org/10.1097/MEG.0000000000001150

Sood S; Haifer C; Yu L; Pavlovic J; Churilov L; Gow PJ; Jones RM; Angus PW; Visvanathan K; Testro AG, 2017, 'A novel immune function biomarker identifies patients at risk of clinical events early following liver transplantation', Liver Transplantation, 23, pp. 487 - 497, http://dx.doi.org/10.1002/lt.24730

Sood S; Haifer C; Yu L; Pavlovic J; Gow PJ; Jones RM; Visvanathan K; Angus PW; Testro AG, 2015, 'Targeted individual prophylaxis offers superior risk stratification for cytomegalovirus reactivation after liver transplantation', Liver Transplantation, 21, pp. 1478 - 1485, http://dx.doi.org/10.1002/lt.24216

Back to profile page